Current pharmacological management of amyotropic lateral sclerosis and a role for rational polypharmacy

Bibliography

• NORRIS F, SHEPHERD R, DENYS E et al.: Onset, natural history and outcome in idiopathic adult motor neuron disease. J. Nemo] ScL (1993) 118(1):48–55.
   PubMed Web of Science ®Google Scholar
• RINGEL SP, MURPHY JR,ALDERSON MK et al.: The natural history of amyotrophic lateral sclerosis. Neurology(1993) 43(7):1316–1322.
   Google Scholar
• NEILSON S, ROBINSON I,ALPEROVITCH A: Rising amyotrophic lateral sclerosis mortality in France 1968-1990: increased life expectancy and inter-disease competition as an explanation. J. Nemo] (1994) 241(7):448–455.
   Google Scholar
• NEILSON S, ROBINSON I,NYMOEN EH: Longitudinal analysis of amyotrophic lateral sclerosis mortality in Norway, 1966-1989: evidence for a susceptible subpopulation. I Neurol Sci. (1994) 122(2):148–154.
   PubMedGoogle Scholar
• EISEN A: Amyotrophic lateral sclerosis is a multifactorial disease. Muscle Nerve (1995) 18(7):741–752.
   PubMedGoogle Scholar
• EISEN A, SCULTZER M, MACNEIL M, PANT B, MAK E: Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve (1993) 16:27–32.
   PubMed Web of Science ®Google Scholar
• PRADAS J, FINISON L, ANDRES PL et al.: The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials. Neurology(1993) 43(4):751–755.
   PubMedGoogle Scholar
• CHANCELLOR AM, WARLOW CP: Adult onset motor neuron disease: worldwide mortality, incidence, and distribution since 1950. J. Nemo] Neurosurg. Psychiatry (1992) 55(12):1106–1115.
   PubMedGoogle Scholar
• NELSON LM, MATKIN CLONGSTRETH WT Jr., MCGUIRE V: Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. II. Diet. Am. J. Epidemiol (2000) 15;151(2):164–73.
   Google Scholar
• NELSON LM, MCGUIRE V, LONGSTRETH WT Jr, MATKIN C. Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption. Am. J. Epidemiol (2000) 151(2):156–63.
   Google Scholar
• SCARMEAS N, SHIH T, STERN Y, OTTMAN R, ROWLAND LP: Premorbid weight, body mass, and varsity athletics in ALS. Neurology (2002) 59(5):773–775.
   PubMedGoogle Scholar
• PLATO CC, GALASKO D,GARRUTO RM et al.: ALS and PDC of Guam: a forty year follow-up. Neurology(2002) 58(5):765–773.
   Google Scholar
• KRIVICKAS LS, YANG J, KIM S, FRONTERA WR: Skeletal muscle fiber function and rate of disease progression in amyotrophic lateral sclerosis. Muscle Nerve (2002) 26:636–643.
   PubMedGoogle Scholar
• MAGNUS T, BECK M, GEISS R et al: Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve (2002) 25(5):709–714.
   PubMed Web of Science ®Google Scholar
• ••This paper identifies clinical parametersthat can be followed to help predict the course of progression in ALS.
   Google Scholar
• PLAITAKIS A, CONSTANTAKAKIS E: Altered metabolism of excitatory amino acids, N-acetyl-aspartate-glutamate in amyotrophic lateral sclerosis. Brain Res. Bull. (1993) 30:381–386.
   PubMed Web of Science ®Google Scholar
• CAMU W, BILLIARD M,BALDY-MOULINER M: Fasting plasma and CSF amino acid levels in ALS.Acta Nemo] Scand. (1993) 88(1):51–55:54.
   Google Scholar
• WIEDEMANN FR, MANFREDI G, MAWEIN C, BEAL ME SCHON EA: Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients.Neurochem. (2002) 80(4):616–625.
   Google Scholar
• ••This paper identifies mechanisms wherebycoenzyme Q10 may prove beneficial in treating ALS.
   Google Scholar
• ROTHSTEIN JD, VAN KAMMEN M, LEVEY AL et al.: Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol (1995) 38:73–84.
   PubMed Web of Science ®Google Scholar
• COURATIER P, HUGON J, SINDOU P, VALLAT JM, DUMAS M: Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to glutamate AMPA/kainate receptors.Lancet (1993) Jan 30;341(8840):265–268.
   Google Scholar
• HEATH PR, SHAW PJ: Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve (2002) 26(4):438–458.
   PubMed Web of Science ®Google Scholar
• ROTHSTEIN JD, MARTIN IJ, KUNCL RW: Decreased glutamate transport by the brain and spinal cord inamyotrophic lateral sclerosis.N. Engl. J. Med. (1992) 326:1464–1468.
   PubMed Web of Science ®Google Scholar
• FERRANTE RJ, BROWNE SE,SHINABU LA et al.: Evidence of increasedoxidative damage in both sporadic and familial amyotrophic lateral sclerosis. Neurochem. (1997) 69(5):2064–2074.
   Google Scholar
• LIU D, WEN J, lIU J, LI L: The roles offree radicals in amyotrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. FASEB J. (1999) 13(15):2318–2328.
   PubMedGoogle Scholar
• SHAW PJ, INCE PG, FALKOUS G, MANTLE D: Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann. Neurol 1995 38(4):691–695.
   PubMed Web of Science ®Google Scholar
• NAKANO Y, HIRAYAMA K, TERAO K: Hepatic ultrastructural changes and liver dysfunction in amyotrophic lateral sclerosis. Arch. Neurol (1987) 44(1):103–106.
   PubMedGoogle Scholar
• SASAKI S, IWATA M: Ultrastructural study of synapses in the anterior horn neurons of patients with amyotrophic lateral sclerosis. NeuroscL Lett. (1996) 204(1-2):53–56.
   PubMed Web of Science ®Google Scholar
• BROWNE SE, BOWLING AC, BIAK MJ et al.: Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis. Neurochem. 1998 71(1):281–287.
   PubMedGoogle Scholar
• FUJITA K, YAMAUCHI M, SHIBAYAMA K et al:Decreased cytochrome c oxidase activity but unchanged superoxide dismutase and glutathione perwddase activities in the spinal cords of patients with amyotrophic lateral sclerosis. J. NeuroscL Res. (1996) 45(3):276–281.
   PubMedGoogle Scholar
• BORTHWICK GM, JOHNSON MA, INCE PG, SHAW PJ, TURNBULL DM: Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann. Neurol (1999) 46(5):787–790.
   PubMed Web of Science ®Google Scholar
• VIELHABER S, KUNZ D, WINKLER K et al.: Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Brain (2000) 123( Pt 7):1339–1348.
   PubMed Web of Science ®Google Scholar
• DHALIWAL GK, GREWAL RP: Mitochondrial DNA deletion mutation levels are elevated in ALS brains. Neuroreport (2000) 11(11):2507–2509.
   PubMedGoogle Scholar
• HAND CK, ROLEAU GA.: Familial amyotrophic lateral sclerosis. Muscle Nerve (2002) 25(2):135–159.
   Google Scholar
• SIDDIQUE T, DENG H: Genetics of ALS. Hum. Mol. Genet. (1996) 5:1465–1470.
   PubMed Web of Science ®Google Scholar
• HOSLER BA, BROWN RH: Copper/zinc superoxide dismutase mutations and free radical damage in amyotrophic lateral sclerosis. Adv. Neurol. (1995) 680:41–46.
   Google Scholar
• LYONS TJ, LIU H, GOTO JJ et al.: Mutations in copper-zinc superoxide dismutase that cause amyotrophic lateral sclerosis alter the zinc binding site and the redux behavior of the protein. Proc. Natl. Acad. Sci. (1996) 93(22):12240–12244.
   PubMedGoogle Scholar
• BRUIJN LI, HOUSEWEART MI, KATO S et al.: Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science (1998) 281(5384):1851–1854.
   PubMed Web of Science ®Google Scholar
• AL-CHALABI A, ANDERSEN PM, NILSSON P et al.: Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum. Mol. Gen. (1999) 8(2):157–164.
   PubMed Web of Science ®Google Scholar
• DRORY VE, BIRNBAUM M, KORCZYN AD, CHAPMAN J: Association of APOE epsilon4 allele with survival in amyotrophic lateral sclerosis.Neurol. Sci (2001) 190(1–2):17–20.
   Google Scholar
• VELDINK JH, VAN DER BERG LH, COBBEN JM et al.: Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic ALS. Neurology (2001) 56(6):749–752.
   Google Scholar
• LAMBRECHTS D, STORKEBAUM E, MORIMOTO M et al.: VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. (2003) 34(4):383–394.
   PubMed Web of Science ®Google Scholar
• •This paper demonstrates a role for a genetic modifier in ALS that might be a target for future therapy.
   Google Scholar
• TROOST D, VAN DEN OORD JJ, DE JONG JM, SWAAB DF: Lymphocytic infiltration in the spinal cord of patients with amyotrophic lateral sclerosis. Clin. Neuropathol. (1989) 8(6):289–294.
   PubMed Web of Science ®Google Scholar
• BANATI RB: Visualizing microglial activation in vivo. Glia (2002) 40(2):206–217.
   PubMed Web of Science ®Google Scholar
• ALEXIANU ME, KOZOVSKA M, APPEL SH: Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology (2001) 57(7):1282–1289.
   PubMed Web of Science ®Google Scholar
• HALL ED, OOSTVEEN JA,GUERNEY ME: Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia (1998) 23(3):249–256.
   Google Scholar
• ELLIOTT JL: Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res. Mol. Brain Res. (2001) 95(1-2):172–178.
   PubMedGoogle Scholar
• YOSHIHARA T, YAMAMOTO M, IWAI K, SOBUE G: Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis.J.Neurochem. (2002) 80(1):158–167.
   Google Scholar
• ••This study identifies a possiblepathophysiological mechanism for neuroinflarnmation in the ALS mouse model.
   Google Scholar
• HENSLEY K, FFLOYD RA, GORDON B et al.: Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J. Neurochem. (2002) 82(6):1570.
   Google Scholar
• ••This study also elucidates possiblepathophysiological mechanisms for neuroinflarnmation in the ALS mouse model.
   Google Scholar
• SIMPSON EP, MOSIER D, APPEL SH: Mechanisms of disease pathogenesis in amyotrophic lateral sclerosis. A central role for calcium. Adv. Neurol (2002) 88:1–19.
   PubMedGoogle Scholar
• OFFEND, HALEVI S, ORION D et al: Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels. Neurology (1998) 51(4):1100–1103.
   PubMedGoogle Scholar
• ENGELHARDT JI, SIKOS L, APPEL SH: Altered calcium homeostasis and ultrastructure in motoneurons of mice caused by passively transferred anti-motoneuronal IgG. Neuropathol. Exp. Neurol. (1997) 56(1):21–39.
   PubMedGoogle Scholar
• APPEL SH, ENGELHARDT JI, GARCIA J, STEFANI E: Immunoglobulins from animal models of motor neuron disease and from human amyotrophic lateral sclerosis patients passively transfer physiological abnormalities to the neuromuscular junction. Proc. Natl. Acad. Sci.USA (1991) 88(2):647–651.
   PubMedGoogle Scholar
• FRATANTONI SA, WEISZ G, PARDAL AM, REISIN RC,UCHITEL OD: Amyotrophic lateral sclerosis IgG-treated neuromuscular junctions develop sensitivity to L-type calcium channel blocker. Muscle Nerve. (2000) 23(4):543–550.
   PubMedGoogle Scholar
• LA BELLA V, GOODMAN JC, APPEL SH: Increased CSF glutamate following injection of ALS immunoglobulins. Neurology (1997) 48(5):1270–1272.
   PubMedGoogle Scholar
• ALEXIANU ME, MOHAMED AH, SMITH RG, COLOM LV, APPEL SH: Apoptotic cell death of a hybrid motoneuron cell line induced by immunoglobulins from patients with amyotrophic lateral sclerosis. Neurochem. (1994) 63(6):2365–2368.
   PubMedGoogle Scholar
• YASOJIMA K, TOURTELLOTTE WW, MCGEER EG, MCGEER PL: Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy.Neurology (2001) 57(6):952–956.
   PubMed Web of Science ®Google Scholar
• MCGEER PL, MCGEER EG: Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve (2002) 26:459–470.
   PubMed Web of Science ®Google Scholar
• ALMER G, TEISMANN P, STEVIC Z et al.: Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology (2002) 58(8):1277–1279.
   PubMed Web of Science ®Google Scholar
• ••This study identifies inflammatory activityin neuronal tissue from humans with ALS.
   Google Scholar
• RAOUL C, ESTEVEZ AG,NISHIMUNE H et al: Motoneuron death triggered by a specific pathway downstream of Fas: potentiation by ALS-Linked SOD1 mutations. Neuron (2002) 35(6):1067.
   PubMed Web of Science ®Google Scholar
• ••This study identifies a possible,mechanism-specific pathway for motor neuron death in ALS.
   Google Scholar
• KLEGERIS A, WALKER DG,MCGEER PL: Regulation of glutamate in cultures of human monocytic THP-1 and astrocytoma U-373 MG cells. Neuroimmunol. (1997) 78(1-2):152–161.
   Google Scholar
• PASINELLI P, HOUSEWEART MK, BROWN RH, CLEVELAND DW: Caspase-1 and -3 are sequentially activated in motor neuron death in Cu, Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis.Proc. Natl. Acad. Sci USA (2000) 97(25):13901–13906.
   Google Scholar
• MARTIN LJ: Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism.i. Neuropathol. Exp. Neurol. (1999) 58(5):459–471.
   Google Scholar
• LI M, ONA VO, GUEGAN C et al.: Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science (2000) 288(5464):335–339.
   PubMed Web of Science ®Google Scholar
• ANSEVIN CF:Treatment of ALS with pleconaril. Neurology (2001)56(5):691–692.
   PubMedGoogle Scholar
• BERGER MM, KOPP N, VITAL C, REDL B, AYMARD M, LINA B: Detection and cellular localization of enterovirus RNA sequences in spinal cord of patients with ALS. Neurology (2000) 54(1):20–25.
   PubMedGoogle Scholar
• WALKER MP, SCHLABERG R, HAYS AP, BOWSER R, LIPKIN WI: Absence of echovirus sequences in brain and spinal cord of amyotrophic lateral sclerosis patients. Ann. Neurol (2001) 49(2):249–253.
   PubMedGoogle Scholar
• MOULIGNIER A, MOULONGUET A, PIALOUX G, ROZENBAUM W: Reversible ALS-like disorder in HIV infection. Neurology (2001) 57(6):995–1001.
   PubMedGoogle Scholar
• MACGOWAN DJ, SCELSA SN, WALDRON M: An ALS-like syndrome with new HIV infection and complete response to antiretroviral therapy. Neurology(2001) 57(6):1094–1097.
   PubMed Web of Science ®Google Scholar
• SUHY J, MILLER RG, RULE R et al: Early detection and longitudinal changes in amyotrophic lateral sclerosis by (1)H MRSI. Neurology (2002) 58(5):773–779.
   PubMed Web of Science ®Google Scholar
• ARASAKI K, KATO Y, HYODA A, USHIJIMA R, TAMAKI M: Longitudinal study of functional spinal alpha motor neuron loss in amyotrophic lateral sclerosis. Muscle Nerve (2002) 25(4):520–526.
   PubMedGoogle Scholar
• GURNEY ME, FLECK TJ, HIMES CS, HALL ED: -Piluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis.Neurology (1998) 50(1):62–66.
   PubMed Web of Science ®Google Scholar
• GURNEY ME, CUTTING FB, ZHAI P et al.: Benefit of vitamin E, riluzole and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol (1996) 39:147–157.
   PubMed Web of Science ®Google Scholar
• BENSIMON G, LACOMBLEZ L, MEININGER V: A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl. I Med. (1994) 330:585–591.
   PubMed Web of Science ®Google Scholar
• MILLER RG, MITCHELL J, MOORE D: Riluzole for amyotrophic lateral sclerosis/motor neuron disease (Cochrane Review). Cochrane Library, Oxford, (2000)
   Google Scholar
• ••An important paper for a systematic reviewof the evidence behind the only FDA-approved treatment for ALS.
   Google Scholar
• MILLER RG, MOORE DH 2nd, GELINAS DF et al: Phase III randomizedtrial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology (2001) 56 (7):843–848.
   PubMed Web of Science ®Google Scholar
• HUBERT JP, DELUMEAU JC, GLOWINSKI J, PREMONT J,DOBLE A: Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action. Br. Pharmacol (1994) 113(1):261–267.
   PubMedGoogle Scholar
• BOIREAU A, MEUNIER M, DOBLE A: 3-Nitropropionic acid exacerbates [3H]GABA release evoked by glucose deprivation in rat striatal slices. Pharm. Pharmacol (1996) 48(1):85–89.
   PubMedGoogle Scholar
• STEFANI A, SPADONI F, BERNARDI G: Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies. Exp. Neuro. (1997) 147(1):115–122.
   PubMed Web of Science ®Google Scholar
• ESTEVEZ AG, STUTZMANN JM, BARBEITO L: Protective effect of riluzole on excitatory amino acid-mediated neurotoxicity in motoneuron-enriched cultures. Eur. Pharmacol (1995) 280(1):47–53.
   PubMedGoogle Scholar
• LACOMBLEZ L, BENSIMON G, LEIGH PN, GUILLET P,MEININGER V: Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet (1996) 347(9013):1425–1431.
   Google Scholar
• NO AUTHORS LISTED: Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole. Neurology (1997) 49:657–659.
   PubMedGoogle Scholar
• ALS CNTF STUDY GROUP: A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology (1996) 46:1244–1249.
   PubMedGoogle Scholar
• BDNF STUDY GROUP: A controlled trial of recombinant methionyl human BDNF in ALS. Neurology (1999) 52:1427–1433.
   PubMedGoogle Scholar
• MILLER RG, PETAJAN JH, BRYAN WW et al.: A placebo-controlled trial of recombinant human ciliary neurotrophic factor in amyotrophic lateral sclerosis. Ann. Neurol (1996) 39(2):256–260.
   PubMed Web of Science ®Google Scholar
• LANGE DJ, FELICE KJ, FESTOFF BW et al.: Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. Neurology (1996) 47:S93–S95.
   Google Scholar
• BORASIO GD, ROBBERECHT W, LEIGH PN, EMILE J et al: A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. Neurology (1998) 51:583–586.
   PubMed Web of Science ®Google Scholar
• MITCHELL JD, WOKKE JH,BORASIO GD: Recombinant human insulin-like growth Factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst. Rev (2002) 3:CD002064.
   Google Scholar
• ANONYMOUS: Xaliproden: SR 57746, SR 57746A, xaliproden hydrochloride, xaliprodene. Drugs RD (2003) 4(6):386–388.
   PubMedGoogle Scholar
• GUO X, DAWSON VL, DAWSON TM: Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. Ear: J. Neurosci. (2001) 13(9):1683–1693.
   PubMedGoogle Scholar
• VYTH A, TIMMER JG, BOSSUYT PM, LOU WERSE ES, DEJONG JM: Survival in patients with amyotrophic lateral sclerosis treated with an array of antioxidants.NeuroL. Sci. (1996) 139(Suppl.):99–103.
   Google Scholar
• DESNUELLE C, DIB M, GARREL C, FAVIER A: A double-blind, placebo-controlled randomized clinical trial of alpha tocopherol (vitamin E) in the treatment of ALS. Amyomoph. Lateral. Scler. Other Motor Neuron Disord (2001) 2:9–18.
   PubMed Web of Science ®Google Scholar
• SHULTS CW, OAKES, D, KEIBURTZ K et al.: Effects of coenzyme Q10 in early Parkinson's disease: evidence of slowing the functional decline. Arch. Neurol (2002) 59(101541–1550.
   Google Scholar
• LANGE DJ, MURPHY PL, DIAMOND B et al.: Selegeline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis.Arch. Neurol (1998) 55:93–96.
   PubMed Web of Science ®Google Scholar
• HULTMAN E, SODERLUND K, TIMMONS JA, CEDERBLAD G, GREENHAFF PL: Muscle creatine loading in men. .1 Appl. Physio. (1996) 81:232–237.
   PubMed Web of Science ®Google Scholar
• TARNAPOLSKY M, MARTIN J: Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology (1999) 52:854–857.
   PubMedGoogle Scholar
• KLIVENYI P, FERRANTE RJ, MATHEWS RT et al.: Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. (1999) 5(3):347–350.
   PubMed Web of Science ®Google Scholar
• SNOW RJ, TURNBULL J, DA SILVA S, JIANG F, TARNAPOLSKY MA: Creatinesupplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice. Neuroscience (2003) 119(3):661–667.
   PubMed Web of Science ®Google Scholar
• PRITCHARD NR, KAIRA PA. Renal dysfunction accompanying oral creatine supplements. Lancet (1998) 351:1252–1253.
   PubMed Web of Science ®Google Scholar
• MAZZINI L, BALZARINI C, COLOMBO R et al.: Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results.Nemo]. Sci. (2001) 191(1–2):139–144.
   Google Scholar
• DRORY VE, GROSS D: No effect of creatine on respiratory distress in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord (2002) 3(1):43–46.loft GROENEVELD GJ, VELDINK JH, VAN DER TWEEL I et al.: A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann. Nemo]. (2003) 53(4):437–445.
   Google Scholar
• SHEFFNERJ: Presentation International ALS Symposium, Nov 2003.
   Google Scholar
• DRACHMAN DB, ROTHSTEIN JD: Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis.Ann. Nemo]. (2000) 48:792–795.
   PubMed Web of Science ®Google Scholar
• DRACHMAN DB, FRANK K, DYKES-HOBERT M et al: Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Nemo]. (2002) 52(6):771–778.
   PubMed Web of Science ®Google Scholar
• ANNESER JMH, COOKSON MR, INCE PG, SHAW PJ, BORASIO GD: Glial cells of the spinal cord and subcortical white matter upregulate nitric oxide synthase in sporadic amyotrophic lateral sclerosis. Exp. Nemo]. (2001) 171:418–421.
   PubMedGoogle Scholar
• BEZZI P, CARMIGNOTO G, PASTI L et al.: Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature (1998) 391(6664):281–285.
   PubMed Web of Science ®Google Scholar
• TIKKA TM, KOISTINAHO JE: Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. brimunol. (2001) 166(12):7527–7533.
   Google Scholar
• YRJANHEIKKI J, KEINANEN R, PELLIKA M, HOKFELT T, KOISTINAHO J: Tetracyclines inhibitmicroglial activation and areneuroprotective in global brain ischemia. Proc. Natl Acad. Sri. USA (1998)95(26):15769–15774.
   PubMed Web of Science ®Google Scholar
• YRJANHEIKKI J, TIKKA T, KEINANEN R et al: A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. USA (1999) 96(23):13496–13500.
   PubMed Web of Science ®Google Scholar
• ZHU S: Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature (2002) 417(6884):74–78.
   PubMed Web of Science ®Google Scholar
• KRIZ J, NGUYEN M, JULIEN J: Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. (2002) 10(3):268.
   PubMed Web of Science ®Google Scholar
• VAN DEN BOSCH L, TILKIN P, LEMMENS G, ROBBERECHT W: Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport (2002) 13(8):1067–1070.
   PubMed Web of Science ®Google Scholar
• ZHANG W, NARAYANAN M, FRIEDLANDER RM: Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann. Nemo]. (2003) 53(2):267–270.
   PubMed Web of Science ®Google Scholar
• ROSENBERG JM, HARRELL C, RISTIC H, WERNER RA,DE ROSAYRO AM: The effect of gabapentin on neuropathic pain. Clin. Pain (1997) 13(3):251–255.
   Google Scholar
• SINDRUP SH, JENSEN TS: Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action.Pain (1999) 83(3):389–400.
   PubMed Web of Science ®Google Scholar
• MILLER RG, MOORED, YOUNG LA et aL:Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Neurology(1996) 47(6):1383–1388.
   Google Scholar
• GREDAL 0, WERDELIN L, BAK S et al: A clinical trial of dextromethorphan in amyotrophic lateral sclerosis. Acta Nemo]. Scand. (1997) 96:8–13.
   PubMed Web of Science ®Google Scholar
• BLIN 0, AZULAY JP, DESNUELLE C et al.: A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosis. Clio. Neuropharm. (1996) 19:189–192.
   Google Scholar
• CUDKOWICZ ME, SHEFNER JM, SCHOENFELD DA et al.: A randomized, placebo-controlled trial of topiramate inamyotrophic lateral sclerosis. Neurology(2003) 61(4):456–464.
   PubMed Web of Science ®Google Scholar
• RYBERG H, ASKMARK H,PERSSON LI: A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters.Acta Nemo]. Scand. (2003) 108(1):1–8.
   Google Scholar
• MILLER RG, SHEPHERD R, DAO H et al.: A controlled trial of nimodipine in amyotrophic lateral sclerosis.Neuromusc. Dis. (1996) 6:101–104.
   PubMed Web of Science ®Google Scholar
• MILLER RG, SMITH SA, MURPHY JR et al.: A clinical trial of verapamil in amyotrophic lateral sclerosis. Muscle Nerve (1996) 19:511–515.
   PubMed Web of Science ®Google Scholar
• BIGINI P, LARINI S, PASQUALI C, MUZIO V, MENNINI T: Acetyl-L-carnitine shows neuroprotective and neurotrophic activity in primary culture of rat embryo motoneurons.NeuroscL Lett. (2002) 329(3):334–338.
   PubMed Web of Science ®Google Scholar
• LOUWERSE ES, WEVERLING GJ, BOSSUYT PM, MEYJES FE, DE JONG JM: Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis.Arch. Nemo]. (1995) 52(6):559–564.
   Google Scholar
• CARTER GT, ROSEN BS: Marijuana in the management of amyotrophic lateral sclerosis. Am. j Hosp. Pa/hat. Care (2001) 18(4):264–270.
   PubMedGoogle Scholar
• CARTER GT, WEYDT P: Cannabis: old medicine with new promise for neurological disorders. Curl-. Opin. Investig. Drugs (2002) 3(3):437–440.
   PubMedGoogle Scholar
• NAGAYAMA T, SINOR AD,SIMPON RP et al.: Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures.NeuroscL (1999) 19(8):2987–2995.
   Google Scholar
• JOLLIET-RIANT P, TILLEMENT JP: Drug transfer across the blood-brain barrier and improvement of brain delivery. Fundam. Chin. Pharmacol (1999) 13(1):16–26 (Review).
   Google Scholar
• MEHTA SH, DHANDAPANI KM, DE SE VILLA LM, WEBB RC,MAHESH VB, BRANN DW:Tamoxifen, a selective estrogen receptor modulator, reduces ischemic damage caused by middle cerebral artery occlusion in the ovariectomized female rat. Neuroendocrinology (2003) 77(1):44–50.
   PubMedGoogle Scholar
• MAENPAA H, MANNERSTROM M, TOIMELA T et al: Glutamate uptake isinhibited by tamoxifen and toremifene in cultured retinal pigment epithelial cells. Pharmacol. Toxicol. (2002) 91(3):116–122.
   PubMedGoogle Scholar
• ANGELOV DN, WAIBEL S, GUNTINAS-LICHIUS 0 et al.: Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc. Natl. Acad. Sd. USA (2003) 100(8):4790–4795.
   Google Scholar
• KATO H, ARAKI T, IMAI Y,TAKAHASHI A, ITOYAMA Y: Protectionof dopaminergic neurons with a novel astrocyte modulating agent(R) ( ) 2 propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease.' Neurol. Sci. (2003) 208(1–2):9–15.
   Google Scholar
• GARBUZOVA-DAVIS S, WILLING AE, ZIGOVA T et al.: Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation.Hematother: Stem Cell Res. (2003)12(3):255–270.
   Google Scholar
• VASTAG B: Stem cells step closer to the clinic: paralysis partially reversed in rats with ALS-like disease. JA/VIA (2001) 285(13):1691–1693.
   Google Scholar
• MAZZINI L, FAGIOLI F,BOCCALETTI R et al.: Stem cell therapy in amyotrophic lateral sclerosis: amethodological approach in humans. Arnyotroph. Lateral Scler. Other Motor Neuron Disord. (2003) 4(3):158–161.
   Google Scholar
• OCHS G, PENN RD, YORK M et al: A Phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Arnyo&oph. Lateral Scler. Other Motor Neuron Disord. (2000) 1(3):201–206.
   PubMed Web of Science ®Google Scholar
• KASPAR BK, LLADO J, SHERKAT N, GAGE FH: Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science (2003) 301(5634):839–842.
   PubMed Web of Science ®Google Scholar
• •This paper identifies a unique system for delivering IGF-1 in an ALS mouse model that could allow for more specific targeting of motor neurons.
   Google Scholar
• ZURN AD, HENRY H, SCHLUEP M et al.: Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically engineered xenogeneic cells. Cell Transplant. (2000) 9(4):471–484.
   PubMedGoogle Scholar
• ZURN AD, WINKEL L, MEN OUD A, DJABALI K, AEBISCHER P: Combined effects of GDNF, BDNF, and CNTF on motoneuron differentiation in vitro.Neurosci. Res. (1996) 44(2):133–141.
   Google Scholar
• MITSUMOTO H, IKEDA K, KLINKOSZ B, CEDARBAUM JM, WONG V, LINDSAY RM: Arrest of motor neuron disease in wobbler mice cotreatedwith CNTF and BDNE Science (1994)265(5175):1107–1110.
   Google Scholar
• KRIZ J, GOWING G, JULIEN JP: Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann. Neurol. (2003) 53(4):429–436.
   PubMedGoogle Scholar
• KLIVENYI P, KIAEI M, GARDIAN G, CALINGASAN NY, BEAL MF: Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. Neurochem. (2004) 88(3):576–582.
   PubMed Web of Science ®Google Scholar
• www.als.mdausa.org Muscular Dystrophy Association Amyotropic Lateral Sclerosis website.
   Google Scholar